It is complicated and I always expected some post hoc analysis of the individual patients. What I didn't expect was the dramatic improvement in the placebo patients at 26 weeks. I don't think I'm alone in that.
With a 52 week study, even if at at the end any improvement in the treatment groups had plateaued, you would think the extra time would have diminished any placebo effect.
Perhaps a question for the AGM would be when will they update us with the 52 week data.
research v. Phase II exam, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $49.27K | 7.039M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 10289318 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1018948 | 1 |
View Market Depth
| Last trade - 15.46pm 11/11/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |